Clinical Trial

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 9, 2024 (before its estimated February 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-24.
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06184698
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Colorectal Cancer
Enrollment 173 participants
Start Date 2024-01-01
Primary Completion 2026-02-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-09